The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Open accessAbstract
BACKGROUND: Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the World Health Organization released a short list of drugs suitable for EVD research. Favipiravir, an antiviral developed for the treatment of severe influenza, was one of these. In late 2014, the conditions for starting a randomized Ebola trial were not fulfilled for two reasons. One was the perception that, given the high number of patients presenting simultaneously and the very high mortality rate of the disease, it was ethically unacceptable to allocate patients from within the same family or village to receive or not receive an experimental drug, using a randomization process impossible to understand by very sick patients. The other was that, in the context of rumors and distrust of Ebola treatment centers, using a randomized design at the outset might lead even more patients to refuse to seek care. Therefore, we chose to conduct a multicenter non-randomized trial, in which all patients would receive favipiravir along with standardized care. The objectives of the trial were to test the feasibility and acceptability of an emergency trial in the context of a large Ebola outbreak, and to collect data on the safety and effectiveness of favipiravir in reducing mortality and viral load in patients with EVD. The trial was not aimed at directly informing future guidelines on Ebola treatment but at quickly gathering standardized preliminary data to optimize the design of future studies. METHODS AND FINDINGS: Inclusion criteria were positive Ebola virus reverse transcription PCR (RT-PCR) test, age ≥ 1 y, weight ≥ 10 kg, ability to take oral drugs, and informed consent. All participants received oral favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d). Semi-quantitative Ebola virus RT-PCR (results expressed in "cycle threshold" [Ct]) and biochemistry tests were performed at day 0, day 2, day 4, end of symptoms, day 14, and day 30. Frozen samples were shipped to a reference biosafety level 4 laboratory for RNA viral load measurement using a quantitative reference technique (genome copies/milliliter). Outcomes were mortality, viral load evolution, and adverse events. The analysis was stratified by age and Ct value. A "target value" of mortality was defined a priori for each stratum, to guide the interpretation of interim and final analysis. Between 17 December 2014 and 8 April 2015, 126 patients were included, of whom 111 were analyzed (adults and adolescents, ≥13 y, n = 99; young children, ≤6 y, n = 12). Here we present the results obtained in the 99 adults and adolescents. Of these, 55 had a baseline Ct value ≥ 20 (Group A Ct ≥ 20), and 44 had a baseline Ct value < 20 (Group A Ct < 20). Ct values and RNA viral loads were well correlated, with Ct = 20 corresponding to RNA viral load = 7.7 log10 genome copies/ml. Mortality was 20% (95% CI 11.6%-32.4%) in Group A Ct ≥ 20 and 91% (95% CI 78.8%-91.1%) in Group A Ct < 20. Both mortality 95% CIs included the predefined target value (30% and 85%, respectively). Baseline serum creatinine was ≥110 μmol/l in 48% of patients in Group A Ct ≥ 20 (≥300 μmol/l in 14%) and in 90% of patients in Group A Ct < 20 (≥300 μmol/l in 44%). In Group A Ct ≥ 20, 17% of patients with baseline creatinine ≥110 μmol/l died, versus 97% in Group A Ct < 20. In patients who survived, the mean decrease in viral load was 0.33 log10 copies/ml per day of follow-up. RNA viral load values and mortality were not significantly different between adults starting favipiravir within <72 h of symptoms compared to others. Favipiravir was well tolerated. CONCLUSIONS: In the context of an outbreak at its peak, with crowded care centers, randomizing patients to receive either standard care or standard care plus an experimental drug was not felt to be appropriate. We did a non-randomized trial. This trial reaches nuanced conclusions. On the one hand, we do not conclude on the efficacy of the drug, and our conclusions on tolerance, although encouraging, are not as firm as they could have been if we had used randomization. On the other hand, we learned about how to quickly set up and run an Ebola trial, in close relationship with the community and non-governmental organizations; we integrated research into care so that it improved care; and we generated knowledge on EVD that is useful to further research. Our data illustrate the frequency of renal dysfunction and the powerful prognostic value of low Ct values. They suggest that drug trials in EVD should systematically stratify analyses by baseline Ct value, as a surrogate of viral load. They also suggest that favipiravir monotherapy merits further study in patients with medium to high viremia, but not in those with very high viremia. TRIAL REGISTRATION: ClinicalTrials.gov NCT02329054.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Severe Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Bellomo, R., Kellum, J. A., & Ronco, C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61454-2 · Cited by 2,598
Rhabdomyolysis and Acute Kidney Injury
Bosch, X., Poch, E., & Grau, J. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801327 · Cited by 1,488
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Emergence of Zaire Ebola Virus Disease in Guinea
Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M. S., Keïta, S., De Clerck, H., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404505 · Cited by 1,366
Self-citationFavipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
The Design and Analysis of Sequential Clinical Trials.
Harrington, D., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 634
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Self-citationClinical Illness and Outcomes in Patients with Ebola in Sierra Leone
Schieffelin, J. S., Shaffer, J. G., Goba, A., Gbakie, M., Gire, S. K., Colubri, A., Sealfon, R. S. G., Kanneh, L., Moigboi, A., Momoh, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411680 · Cited by 530
Towner, J. S., Rollin, P. E., Bausch, D. G., Sanchez, A., Crary, S. M., Vincent, M., Lee, W. F., Spiropoulou, C. F., Ksiazek, T. G., Lukwiya, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4330-4341.2004 · Cited by 515
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Self-citationMaximum likelihood estimation in nonlinear mixed effects models
Kuhn, E., & Lavielle, M. (2005) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2004.07.002 · Cited by 480
Bacterial, Fungal, Parasitic, and Viral Myositis
Crum-Cianflone, N. F. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-08 · Cited by 422
Human asymptomatic Ebola infection and strong inflammatory response
Leroy, E., Baize, S., Volchkov, V., Fisher-Hoch, S., Georges-Courbot, M.-C., Lansoud-Soukate, J., Capron, M., Debré, P., Georges, A., & McCormick, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02405-3 · Cited by 411
Self-citationRowe, A. K., Bertolli, J., Khan, A. S., Mukunu, R., Muyembe‐Tamfum, J. J., Bressler, D., Williams, A. J., Peters, C. J., Rodriguez, L., Feldmann, H., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/514318 · Cited by 387
Clinical Presentation of Patients with Ebola Virus Disease in Conakry, Guinea
Bah, E. I., Lamah, M.-C., Fletcher, T., Jacob, S. T., Brett-Major, D. M., Sall, A. A., Shindo, N., Fischer, W. A., Lamontagne, F., Saliou, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411249 · Cited by 386
Self-citationMultivariate or Multivariable Regression?
Hidalgo, B., & Goodman, M. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.300897 · Cited by 365
Ksiazek, T. G., Rollin, P. E., Williams, A. J., Bressler, D. S., Martin, M. L., Swanepoel, R., Burt, F. J., Leman, P. A., Khan, A. S., Rowe, A. K., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/514321 · Cited by 359
Clinical Care of Two Patients with Ebola Virus Disease in the United States
Lyon, G. M., Mehta, A. K., Varkey, J. B., Brantly, K., Plyler, L., McElroy, A. K., Kraft, C. S., Towner, J. S., Spiropoulou, C., Ströher, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409838 · Cited by 337
Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever
Kortepeter, M. G., Bausch, D. G., & Bray, M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir299 · Cited by 328
Tam, N. T., Huy, N. T., Thoa, L. T. B., Long, N. P., Trang, N. T. H., Hirayama, K., & Karbwang, J. (2015) · Bulletin of the World Health Organization · doi:10.2471/blt.14.141390 · Cited by 315
Sanchez, A., Lukwiya, M., Bausch, D., Mahanty, S., Sanchez, A. J., Wagoner, K. D., & Rollin, P. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10370-10377.2004 · Cited by 281
Smither, S. J., Eastaugh, L. S., Steward, J. A., Nelson, M., Lenk, R. P., & Lever, M. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.012 · Cited by 228
Broadhurst, M. J., Kelly, J. D., Miller, A., Semper, A., Bailey, D., Groppelli, E., Simpson, A., Brooks, T., Hula, S., Nyoni, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61042-x · Cited by 205
Hunt, L., Gupta-Wright, A., Simms, V., Tamba, F., Knott, V., Tamba, K., Heisenberg-Mansaray, S., Tamba, E., Sheriff, A., Conteh, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00144-9 · Cited by 204
Randomised controlled trials for Ebola: practical and ethical issues
Adebamowo, C., Bah-Sow, O., Binka, F., Bruzzone, R., Caplan, A., Delfraissy, J.-F., Heymann, D., Horby, P., Kaleebu, P., Tamfum, J.-J. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61734-7 · Cited by 178
Varghese, J. M., Roberts, J. A., & Lipman, J. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.09.006 · Cited by 159
Copas, J. B. (1983) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.2307/2348040 · Cited by 158
Rollin, P. E., Bausch, D. G., & Sanchez, A. (2007) · The Journal of Infectious Diseases · doi:10.1086/520613 · Cited by 149
Structural basis for Marburg virus VP35–mediated immune evasion mechanisms
Ramanan, P., Edwards, M. R., Shabman, R. S., Leung, D. W., Endlich-Frazier, A., Borek, D., Otwinowski, Z., Liu, G., Huh, J., Basler, C. F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213559109 · Cited by 142
Mora-Rillo, M., Arsuaga, M., Olivencia, G. R., Calle, F., Borobia, A. M., Sánchez-Seco, P., Lago, M., Figueira, J. C., Fernández-Puntero, B., Viejo, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00180-0 · Cited by 128
Fitzpatrick, G., VOGT, F. M., Gbabai, O., Decroo, T., Keane, M., Clerck, H. D., Grolla, A., Brechard, R., Stinson, K., & Herp, M. V. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv304 · Cited by 113
The Design and Analysis of Sequential Clinical Trials (2nd ed.).
Lachenbruch, P. A., & Whitehead, J. (1993) · Journal of the American Statistical Association · doi:10.2307/2290372 · Cited by 108
Clinical Presentation and Management of Severe Ebola Virus Disease
West, T. E., & Arnim, A. V. S. A.-V. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201410-481ps · Cited by 94
Kuhn, J. H., Andersen, K. G., Baize, S., Bào, Y., Bavari, S., Berthet, N., Blinkova, O., Brister, J. R., Clawson, A. N., Fair, J. N., et al. (2014) · Viruses · doi:10.3390/v6114760 · Cited by 93
Self-citationReaching out to Ebola victims: Coercion, persuasion or an appeal for self-sacrifice?
Calain, P., & Poncin, M. (2015) · Social Science & Medicine · doi:10.1016/j.socscimed.2015.10.063 · Cited by 88
Self-citationFiloviral Immune Evasion Mechanisms
Ramanan, P., Shabman, R. S., Brown, C. S., Amarasinghe, G. K., Basler, C. F., & Leung, D. W. (2011) · Viruses · doi:10.3390/v3091634 · Cited by 86
Evaluating Novel Therapies During the Ebola Epidemic
Joffe, S. (2014) · JAMA · doi:10.1001/jama.2014.12867 · Cited by 76
Schibler, M., Vetter, P., Cherpillod, P., Petty, T. J., Cordey, S., Vieille, G., Yerly, S., Siegrist, C., Samii, K., Dayer, J.-A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00229-7 · Cited by 58
Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays
Huang, Y. P., Wei, H., Wang, Y., Shi, Z., Raoul, H., & Yuan, Z. (2012) · Virologica Sinica · doi:10.1007/s12250-012-3252-y · Cited by 54
Self-citationFavipiravir for children with Ebola
Bouazza, N., Tréluyer, J., Foissac, F., Mentré, F., Taburet, A., Guedj, J., Anglaret, X., de Lamballerie, X. N., Keïta, S., Malvy, D. J.-M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60232-x · Cited by 51
Self-citationEvaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease
Cooper, B. S., Boni, M. F., Ngum, W. P., Day, N., Horby, P., Olliaro, P., Lang, T. A., White, N. J., White, L. J., & Whitehead, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001815 · Cited by 48
Victory, K. R., Coronado, F., Ifono, S. O., Soropogui, T., & Dahl, B. A. (2015) · PubMed Central · Cited by 47
Lanini, S., Zumla, A. I., Ioannidis, J. P. A., Di, A., Krishna, S., Gostin, L. O., Girardi, E., Pletschette, M., Strada, G., Baritussio, A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70106-4 · Cited by 44
Kourtis, A. P., Appelgren, K. E., Chevalier, M. S., & McElroy, A. K. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000707 · Cited by 40
Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa
Stephens, D. S., Ribner, B. S., Gartland, B. D., Feistritzer, N. R., Farley, M. M., Larsen, C. P., & Fox, J. T. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001857 · Cited by 22
Cited by
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
Metadata
- Authors
- Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., Carazo, S., Conde, M. N., Gala, J.-L., Colin, G., Savini, H., Bore, J. A., Le Marcis, F., Koundouno, F. R., Petitjean, F., Lamah, M.-C., Diederich, S., Tounkara, A., Poelart, G., Berbain, E., Dindart, J.-M., Duraffour, S., Lefevre, A., Leno, T., Peyrouset, O., Irenge, L., Bangoura, N., Palich, R., Hinzmann, J., Kraus, A., Barry, T. S., Berette, S., Bongono, A., Camara, M. S., Chanfreau Munoz, V., Doumbouya, L., Harouna, S., Kighoma, P. M., Koundouno, F. R., Lolamou, R., Loua, C. M., Massala, V., Moumouni, K., Provost, C., Samake, N., Sekou, C., Soumah, A., Arnould, I., Komano, M. S., Gustin, L., Berutto, C., Camara, D., Camara, F. S., Colpaert, J., Delamou, L., Jansson, L., Kourouma, E., Loua, M., Malme, K., Manfrin, E., Maomou, A., Milinouno, A., Ombelet, S., Sidiboun, A. Y., Verreckt, I., Yombouno, P., Bocquin, A., Carbonnelle, C., Carmoi, T., Frange, P., Mely, S., Nguyen, V.-K., Pannetier, D., Taburet, A.-M., Treluyer, J.-M., Kolie, J., Moh, R., Gonzalez, M. C., Kuisma, E., Liedigk, B., Ngabo, D., Rudolf, M., Thom, R., Kerber, R., Gabriel, M., Di Caro, A., Wölfel, R., Badir, J., Bentahir, M., Deccache, Y., Dumont, C., Durant, J.-F., El Bakkouri, K., Gasasira Uwamahoro, M., Smits, B., Toufik, N., Van Cauwenberghe, S., Ezzedine, K., Dortenzio, E., Pizarro, L., Etienne, A., Guedj, J., Fizet, A., Barte de Sainte Fare, E., Murgue, B., Tran-Minh, T., Rapp, C., Piguet, P., Poncin, M., Draguez, B., Allaford Duverger, T., Barbe, S., Baret, G., Defourny, I., Carroll, M., Raoul, H., Augier, A., Eholie, S. P., Yazdanpanah, Y., Levy-Marchal, C., Antierrens, A., Van Herp, M., Günther, S., de Lamballerie, X., Keïta, S., Mentre, F., Anglaret, X., Malvy, D., & JIKI Study Group
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-01
- Volume
- 13
- Issue
- 3
- Pages
- e1001967
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2296414617
- Cited by
- 478
- References
- 49
- FWCI
- 56.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.